Clinical effects and cases of belumosudil in the treatment of pulmonary rejection

Belumosudil is a selective Rho-related protein kinase2 (ROCK2) inhibitors are mainly used to treat chronic graft-versus-host disease (cGVHD), especially showing potential clinical effects in lung graft-versus-host reaction (pulmonary rejection). Pulmonary rejection is a common and serious complication after lung transplantation. It manifests as airway inflammation and fibrosis, leading to the gradual deterioration of lung function and making treatment difficult. Besudil helps reduce inflammation and lung tissue damage by modulating immune cell function and anti-fibrotic effects.

In clinical trials, besudil has shown positive effects on chronic GVHD in the lungs. After receiving besudil treatment, some patients have improved pulmonary function tests (such as vital capacity and air flow), and clinical symptoms such as dyspnea, cough and lung inflammation have been significantly reduced. The drug not only improves lung symptoms but also improves patients' quality of life, especially for patients who have had an inadequate response to traditional immunosuppressants.

In terms of specific cases, a multi-center clinical study reported a patient with chronic lung rejection after lung transplantation. Besudil was added to the standard treatment when the effect was poor. After several months of treatment, the patient's lung function improved significantly. Imaging examination showed that lung inflammation was reduced, respiratory symptoms were relieved, and the ability to live activities was improved without serious side effects. This reflects the clinical application potential of besudil in lung rejection.

In general, besudil, as a ROCK2 inhibitor, provides a new therapeutic idea in the treatment of pulmonary rejection, especially in anti-fibrosis and regulating immunity. Although relevant research is still ongoing, besudil provides a promising treatment option for lung transplant patients. As more clinical data accumulates in the future, its application prospects will be broader.

Reference materials:https://www.drugs.com/